Accès gratuit
Numéro
Med Sci (Paris)
Volume 28, Numéro 10, Octobre 2012
Page(s) 813 - 816
Section Nouvelles
DOI https://doi.org/10.1051/medsci/20122810005
Publié en ligne 12 octobre 2012
  1. Central brain tumor registry of the United States. www.cbtrus.org (consulté le 26 avril 2012).
  2. Van den Bent MJ. Interobserver variation of the histopathological diagnosis in clinical trials on glioma : a clinician’s perspective. Acta Neuropathol 2010 ; 120 : 297–304. [CrossRef] [PubMed]
  3. Smith JS, Perry A, Borell TJ, et al. Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. J Clin Oncol 2000 ; 18 : 636–645. [PubMed]
  4. Quon H, Abdulkarim B. Adjuvant treatment of anaplastic oligodendrogliomas and oligoastrocytomas. Cochrane Database Syst Rev 2008 : CD007104. [PubMed]
  5. Houillier C, Wang X, Kaloshi G, et al. IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas. Neurology 2010 ; 75 : 1560–1566. [CrossRef] [PubMed]
  6. Hegi ME, Diserens AC, Godard S, et al. Clinical trial substantiates the predictive value of 0-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. Clin Cancer Res 2004 ; 10 : 1871–1874. [CrossRef] [PubMed]
  7. Everhard S, Kaloshi G, Criniere E, et al. MGMT methylation : a marker of response to temozolomide in low-grade gliomas. Ann Neurol 2006 ; 60 : 740–743. [CrossRef] [PubMed]
  8. Snuderl M, Fazlollahi L, Le LP, et al. Mosaic amplification of multiple receptor tyrosine kinase genes in glioblastoma. Cancer Cell 2011 ; 20 : 810–817. [CrossRef] [PubMed]
  9. Juillerat-Jeanneret L, Bernasconi CC, Bricod C, et al. Heterogeneity of human glioblastoma : glutathione-S-transferase and methylguanine-methyltransferase. Cancer Invest 2008 ; 26 : 597–609. [CrossRef] [PubMed]
  10. Bonavia R, Inda MM, Cavenee WK, et al. Heterogeneity maintenance in glioblastoma: a social network. Cancer Res 2011 ; 71 : 4055–4060. [CrossRef] [PubMed]
  11. Yung WK, Vredenburgh JJ, Cloughesy TF, et al. Safety and efficacy of erlotinib in first-relapse glioblastoma: a phase II open-label study. Neuro Oncol 2010 ; 12 : 1061–1070. [CrossRef] [PubMed]
  12. Paulsson J, Lindh MB, Jarvius M, et al. Prognostic but not predictive role of platelet-derived growth factor receptors in patients with recurrent glioblastoma. Int J Cancer 2010 ; 128 : 1981–1988. [CrossRef]
  13. Natsume A, Kinjo S, Yuki K, et al. Glioma-initiating cells and molecular pathology: implications for therapy. Brain Tumor Pathol 2011 ; 28 : 1–12. [CrossRef] [PubMed]
  14. Ducray F, Mokhtari K, Criniere E, et al. Diagnostic and prognostic value of alpha internexin expression in a series of 409 gliomas. Eur J Cancer 2011 ; 47 : 802–808. [CrossRef] [PubMed]
  15. SongTao Q, Lei Y, Si G, et al. IDH mutations predict longer survival and response to temozolomide in secondary glioblastoma. Cancer Sci 2011 ; 103 : 269–273. [CrossRef] [PubMed]
  16. Van den Bent MJ, Dubbink HJ, Sanson M, et al. MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: a report from EORTC Brain Tumor Group Study 26951. J Clin Oncol 2009 ; 27 : 5881–5886. [CrossRef] [PubMed]
  17. Jha P, Suri V, Jain A, et al. 06-methylguanine DNA methyltransferase gene promoter methylation status in gliomas and its correlation with other molecular alterations: first Indian report with review of challenges for use in customized treatment. Neurosurgery 2010 ; 67 : 1681–1691. [CrossRef] [PubMed]
  18. Zawlik I, Vaccarella S, Kita D, et al. Promoter methylation and polymorphisms of the MGMT gene in glioblastomas: a population-based study. Neuroepidemiology 2009 ; 32 : 21–29. [CrossRef] [PubMed]
  19. Singh SK, Clarke ID, Terasaki M, et al. Identification of a cancer stem cell in human brain tumors. Cancer Res 2003 ; 63 : 5821–5828. [PubMed]
  20. Molina JR, Hayashi Y, Stephens C, et al. Invasive glioblastoma cells acquire stemness and increased Akt activation. Neoplasia 2010 ; 12 : 453–463. [PubMed]
  21. Hoelzinger DB, Mariani L, Weis J, et al. Gene expression profile of glioblastoma multiforme invasive phenotype points to new therapeutic targets. Neoplasia 2005 ; 7 : 7–16. [CrossRef] [PubMed]
  22. Gole B, Huszthy PC, Popovic M, et al. The regulation of cysteine cathepsins and cystatins in human gliomas. Int J Cancer 2012 (online). doi : 10.1002/ijc.27453.
  23. Mariani L, Beaudry C, McDonough WS, et al. Death-associated protein 3 (Dap-3) is overexpressed in invasive glioblastoma cells in vivo and in glioma cell lines with induced motility phenotype in vitro. Clin Cancer Res 2001 ; 7 : 2480–2489. [PubMed]
  24. Seidel S, Garvalov BK, Wirta V, et al. A hypoxic niche regulates glioblastoma stem cells through hypoxia inducible factor 2 alpha. Brain 2010 ; 133 : 983–995. [CrossRef] [PubMed]
  25. Rong Y, Durden DL, Van Meir EG, et al. Pseudopalisading necrosis in glioblastoma: a familiar morphologic feature that links vascular pathology, hypoxia, and angiogenesis. J Neuropathol Exp Neurol 2006 ; 65 : 529–539. [CrossRef] [PubMed]
  26. Charalambous C, Chen TC, Hofman FM. Characteristicsof tumor-associated endothelial cells derived from glioblastoma multiforme. Neurosurg Focus 2006 ; 20 : E22. [CrossRef] [PubMed]
  27. Miebach S, Grau S, Hummel V, et al. Isolation and culture of microvascular endothelial cells from gliomas of different WHO grades. J NeuroOncol 2006 ; 76 : 39–48. [CrossRef] [PubMed]
  28. Dahlstrand J, Collins VP, Lendahl U. Expression of the class VI intermediate filament nestin in human central nervous system tumors. Cancer Res 1992 ; 52 : 5334–5341. [PubMed]
  29. Shih AH, Holland EC. Notch signaling enhances nestin expression in gliomas. Neoplasia 2006 ; 8 : 1072–1082. [CrossRef] [PubMed]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.